SYCUME® blocks the activation of IGF-1R signaling pathway mediated by IGF-1 and related ligands or agonistic antibodies, reducing the expression of downstream inflammatory factors. This ...

which similarly reduced IGF-1R signaling. Their findings suggest that, like findings hitherto exclusively observed in model organisms, the highly conserved IGF-1 axis is associated with human ...

As China's first and the world's second approved IGF-1R antibody drug, SYCUME ® has ended a 70-year drought of no new treatment option for TED in China. This groundbreaking therapy will redefine ...